Gothenburg, Sweden, 2015-04-17 17:35 CEST (GLOBE NEWSWIRE) -- CEO Jamal El-Mosleh and Chief Scientific Officer Alex Karlsson-Parra in Immunicum AB (publ) have for personal financial reasons sold a small amount of their shares in the Company. They still maintain more than 85% of their previous total holdings.
Jamal El-Mosleh’s total amount of shares, after sale of 67,000 shares, amounts to 383,000 shares. Alex Karlsson-Parra's total amount of shares, including shares of related parties, amounts, after the sale of 100,000 shares, to 602,726 shares.
"We have worked many years at Immunicum and this is the first time we sell a few shares for purely personal financial reasons. We have a very strong belief in the Company's future and are not aware of any negative information that could affect the Company's business. Everything goes according to plan", said CEO Jamal El-Mosleh.
For further information, please contact:
Jamal El-Mosleh, CEO, Immunicum, 031-41 50 52,
jamal.el-mosleh@immunicum.com
www.immunicum.com
Certified Adviser Redeye AB
Tel: 08-545013 31. www.redeye.se
About Immunicum
Immunicum AB (publ) develops therapeutic cancer vaccines. A phase II study of the Company's most advanced project - INTUVAX® against renal cancer - has been approved by the Swedish Medical Products Agency and is expected to start in spring 2015. The project portfolio contains three additional projects against various tumors, including an ongoing clinical study in patients with liver cancer.